Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VV116 versus Paxlovid for early treatment of mild to moderate COVID-19 in high-risk adults
ChiCTR2200057856Phase 3Completed
- Sponsor
- Ruijin Hospital
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of deuremidevir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Time to sustained clinical recovery. Started Mar 2022; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200057856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057856.